For research use only
| Cat No. | ABC-X0145C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Host Cell | HEK293T |
| Source Organ | Kidney |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The Xpress™ RANKL HEK293T cell line offers a stable model for studying bone resorption and immune responses, perfect for cancer and inflammatory research.
Xpress™ Human RANKL over-expressing cell line (HEK293T) is a genetically engineered model derived from selected human embryonic kidney 293T parental cell line based on customers’ requirement. RANKL HEK293T overexpression cell line is generated by stable integration of exogenous human RANKL (TNFSF11) into HEK293T host cells using our optimized transduction of lentiviral vectors. Overexpression clone is validated at gene level by qRT-PCR.
Target
The RANKL gene encodes a key member of the tumor necrosis factor (TNF) superfamily that regulates osteoclast differentiation, bone resorption, and immune responses. Overexpression of RANKL contributes to osteolytic lesions in cancers such as breast and prostate cancer, and it plays a crucial role in the tumor-bone microenvironment. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0145C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Kidney |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | HEK293T |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The RANKL HEK293T Overexpression Cell Line is ideal for studying bone metastasis, osteoclast activation, and tumor–bone interactions. It supports screening of RANKL-targeting agents such as denosumab in bone-related oncologic and inflammatory research.